Clinical Trial Update: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) [Phase 3]

View source ↗

Summary

This Phase 3 trial DESTINY-Breast09 is evaluating trastuzumab deruxtecan with or without pertuzumab versus a taxane-based regimen plus trastuzumab and pertuzuma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Taxane (paclitaxel or docetaxel)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer; HER2-positive; Metastatic | Phase 3 | Status: ACTIVE_NOT_RECRUITING